Israel’s public-sector labor union staged a strike yesterday to protest Teva Pharmaceuticals‘ (NYSE:TEVA) move to cut more than 25% of its global workforce in an effort to restructure the company. Teva is one of Israel’s largest companies and its decision to close an Israel-based manufacturing site and slash jobs has angered groups in Israel, who point […]
Allergan
Restasis buyers level antitrust lawsuit against Allergan
A proposed class of Restasis buyers filed an antitrust suit last week in a Texas federal court against Allergan (NYSE:AGN), according to reports from Law360. The suit accuses Allergan of blocking generics to its dry-eye drug using tactics like sham infringement suits and a controversial deal with a Native American tribe. In September, Allergan struck a deal […]
Allergan’s intravitreal implant wins approval in China
Allergan (NYSE:AGN) said today that it landed an imported drugs license from the Chinese FDA to market its dexamethasone intravitreal implant, Ozurdex, as a treatment for adults with macular edema following branch retinal vein occlusion or central retinal vein occlusion. The Dublin-based pharma giant touted its therapy as the first intravitreal injection approved for RVO in […]
The 11 most innovative medical devices of 2017
The nominees for the best medical technology of 2017 were recently announced for the 11th Annual Prix Galien USA Awards. The Galien Foundation, the host of the awards, hands out the Prix Galien Award annually to examples of outstanding biomedical and technology product achievement designed to improve human condition. Before candidates can qualify for the […]
Mylan: Allergan’s legal move with tribe reveals “duplicitousness” towards patent system
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year. The decision came […]
Texas judge rules Allergan’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today. The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals […]
Milestone Scientific names interim chief executive | Personnel Moves – Oct. 13, 2017
Milestone Scientific (NYSE:MLSS) said last week that chairman of the board Leslie Bernhard will take over as interim CEO after former president & CEO Daniel Goldberger resigned at the start of this month. The Livingston, N.J.-based company is conducting a formal search for a new CEO as the board of directors evaluates options for its CompuFlo […]
Allergan settles Restasis patent challenge after moving patents to Native American tribe
Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis. InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in […]
Azura Ophthalmics raises $16m for meibomian gland dysfunction therapy
Biotech Azura Ophthalmics said today that it closed a $16 million Series B round led by a syndicate of OrbiMed, TPG Biotech and Brandon Capital’s Medical Research Commercialization Fund. Existing investor Ganot Capital also participated in the round. The investment is slated to support Azura’s development of a drug for a leading cause of dry […]
Allergan alleges Imprimis makes, sells and promotes unapproved drugs – and Imprimis fires back
Last week, Allergan (NYSE:AGN) said that it filed lawsuits against Imprimis Pharmaceuticals (NSDQ:IMMY), Prescriber’s Choice and Sincerus Florida, claiming that the companies manufacture, sell and promote unapproved new drugs. The pharmaceutical giant filed suit in the U.S. District Court for the Central District of California. Today, Imprimis fired back at Allergan, denying the allegations and saying that […]
